Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 11/2021

19.05.2021 | Original Article

Comparative activities of sitafloxacin against recent clinical isolates in hospitals across China

verfasst von: Shi Wu, Yang Yang, Yan Guo, Dandan Yin, Yonggui Zheng, Renru Han, Li Ding, Demei Zhu, Fupin Hu

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 11/2021

Einloggen, um Zugang zu erhalten

Abstract

Sitafloxacin is one of the newer generation fluoroquinolones. Considering the ever-changing antimicrobial resistance, it is necessary to monitor the activities of sitafloxacin against recent pathogenic isolates. Therefore, we determined the minimum inhibitory concentrations (MICs) of sitafloxacin and comparators by broth microdilution or agar dilution method against 1101 clinical isolates collected from 2017 to 2019 in 31 hospitals across China. Sitafloxacin was highly active against gram-positive isolates evidenced by the MICs required to inhibit the growth of 50%/90% isolates (MIC50/90): ≤ 0.03/0.25, ≤ 0.03/0.125, ≤ 0.03/2, 0.125/0.25, 0.25/2, and 0.125/0.125 mg/L for methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-susceptible coagulase-negative Staphylococcus (MSCNS), methicillin-resistant S. aureus (MRSA), methicillin-resistant CNS, Enterococcus faecalis, and Streptococcus pneumoniae, respectively. Sitafloxacin inhibited 82.8% of the MRSA strains and 97.5% of MRCNS strains. Sitafloxacin was also potent against ciprofloxacin-susceptible Escherichia coli (MIC50/90: ≤ 0.03/0.06 mg/L) and Klebsiella pneumoniae (MIC50/90: ≤ 0.03/0.125 mg/L), non-ESBL-producing E. coli (MIC50/90: ≤ 0.03/1 mg/L) and K. pneumoniae (MIC50/90: ≤ 0.03/0.5 mg/L), Haemophilus influenzae (MIC50/90: ≤0.015/0.06 mg/L), Haemophilus parainfluenzae (MIC50/90: 0.125/0.5 mg/L), Moraxella catarrhalis (MIC50/90: ≤ 0.015/≤ 0.015 mg/L), Bacteroides fragilis (MIC50/90: 0.06/2 mg/L), Peptostreptococcus (MIC50/90: 0.125/4 mg/L), and Mycoplasma pneumoniae (≤ 0.03/≤ 0.03 mg/L). However, sitafloxacin was less active for Enterococcus faecium, ciprofloxacin-resistant and/or ESBL-producing E. coli, and K. pneumoniae strains. Sitafloxacin was superior or comparable to most of the comparators in activities against the abovementioned isolates, so sitafloxacin is still highly active against most of the clinical isolates in hospitals across China, proving its utility in treatment of the abovementioned susceptible strains.
Literatur
1.
Zurück zum Zitat Asakura T, Suzuki S, Fukano H et al (2019) Sitafloxacin-containing regimen for the treatment of refractory Mycobacterium avium complex lung disease. Open Forum Infect Dis 6:ofz108CrossRef Asakura T, Suzuki S, Fukano H et al (2019) Sitafloxacin-containing regimen for the treatment of refractory Mycobacterium avium complex lung disease. Open Forum Infect Dis 6:ofz108CrossRef
2.
Zurück zum Zitat Manosuthi W, Wiboonchutikul S (2016) Treatment outcomes of oral sitafloxacin in acute complicated urinary tract infection and pyelonephritis. Springerplus 5:410CrossRef Manosuthi W, Wiboonchutikul S (2016) Treatment outcomes of oral sitafloxacin in acute complicated urinary tract infection and pyelonephritis. Springerplus 5:410CrossRef
3.
Zurück zum Zitat Keating GM (2011) Sitafloxacin: in bacterial infections. Drugs 71:731–744CrossRef Keating GM (2011) Sitafloxacin: in bacterial infections. Drugs 71:731–744CrossRef
4.
Zurück zum Zitat Hamasuna R, Ohnishi M, Matsumoto M et al (2018) In Vitro activity of sitafloxacin and additional newer generation fluoroquinolones against ciprofloxacin-resistant Neisseria gonorrhoeae isolates. Microb Drug Resist 24:30–34CrossRef Hamasuna R, Ohnishi M, Matsumoto M et al (2018) In Vitro activity of sitafloxacin and additional newer generation fluoroquinolones against ciprofloxacin-resistant Neisseria gonorrhoeae isolates. Microb Drug Resist 24:30–34CrossRef
5.
Zurück zum Zitat Tantisiriwat W, Linasmita P (2017) In vitro activity of sitafloxacin and other antibiotics against bacterial isolates from HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University and Samitivej Sukhumvit Hospital. J Med Assoc Thail 100:469–478 Tantisiriwat W, Linasmita P (2017) In vitro activity of sitafloxacin and other antibiotics against bacterial isolates from HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University and Samitivej Sukhumvit Hospital. J Med Assoc Thail 100:469–478
6.
Zurück zum Zitat Xu N, Wang G, Leng Y et al (2018) Sulbactam enhances the in vitro activity of sitafloxacin against extensively-drug resistant Acinetobacter baumannii. ExpTher Med 16:3485–3491 Xu N, Wang G, Leng Y et al (2018) Sulbactam enhances the in vitro activity of sitafloxacin against extensively-drug resistant Acinetobacter baumannii. ExpTher Med 16:3485–3491
7.
Zurück zum Zitat Clinical and Laboratory Standards Institute (2020) Performance standards for antimicrobial susceptibility testing; M100 30th. Clin Lab Stand Instit Clinical and Laboratory Standards Institute (2020) Performance standards for antimicrobial susceptibility testing; M100 30th. Clin Lab Stand Instit
8.
Zurück zum Zitat CLSI (2018) M07, 11th Ed. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Clinical and Laboratory Standards Institute, Wayne CLSI (2018) M07, 11th Ed. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Clinical and Laboratory Standards Institute, Wayne
9.
Zurück zum Zitat CLSI (2011) Methods for antimicrobial susceptibility testing for human mycoplasmas; approved guideline (M43-A). Clinical and Laboratory Standards Institute, Wayne CLSI (2011) Methods for antimicrobial susceptibility testing for human mycoplasmas; approved guideline (M43-A). Clinical and Laboratory Standards Institute, Wayne
10.
Zurück zum Zitat Hu F, Guo Y, Yang Y et al (2019) Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis 38:2275–2281CrossRef Hu F, Guo Y, Yang Y et al (2019) Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis 38:2275–2281CrossRef
11.
Zurück zum Zitat Milatovic D, Schmitz FJ, Brisse S, Verhoef J, Fluit AC (2000) In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrob Agents Chemother 44:1102–1107CrossRef Milatovic D, Schmitz FJ, Brisse S, Verhoef J, Fluit AC (2000) In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrob Agents Chemother 44:1102–1107CrossRef
12.
Zurück zum Zitat Schmitz FJ, Fluit AC, Milatovic D et al (2000) In vitro potency of moxifloxacin, clinafloxacin and sitafloxacin against 248 genetically defined clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 46:109–113CrossRef Schmitz FJ, Fluit AC, Milatovic D et al (2000) In vitro potency of moxifloxacin, clinafloxacin and sitafloxacin against 248 genetically defined clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 46:109–113CrossRef
13.
Zurück zum Zitat Amano A, Matsuzaki K, Kishi N et al (2013) In vitro activity of sitafloxacin against clinical isolates in 2012. Jpn J Antibiot 66:311–330 [Japanese]CrossRef Amano A, Matsuzaki K, Kishi N et al (2013) In vitro activity of sitafloxacin against clinical isolates in 2012. Jpn J Antibiot 66:311–330 [Japanese]CrossRef
14.
Zurück zum Zitat Doern GV, Heilmann KP, Huynh HK et al (2001) Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 45:1721–1729CrossRef Doern GV, Heilmann KP, Huynh HK et al (2001) Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 45:1721–1729CrossRef
15.
Zurück zum Zitat Snydman DR, Jacobus NV, McDermott LA et al (2002) In vitro activities of newer quinolones against Bacteroides group organisms [Errata in Antimicrob Agents Chemother 2003;47(2):831]. Antimicrob Agents Chemother 46:3276–3279CrossRef Snydman DR, Jacobus NV, McDermott LA et al (2002) In vitro activities of newer quinolones against Bacteroides group organisms [Errata in Antimicrob Agents Chemother 2003;47(2):831]. Antimicrob Agents Chemother 46:3276–3279CrossRef
16.
Zurück zum Zitat Tanigawara Y, Kaku M, Totsuka K, Tsuge H, Saito A (2013) Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections. J Infect Chemother 19:858–866CrossRef Tanigawara Y, Kaku M, Totsuka K, Tsuge H, Saito A (2013) Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections. J Infect Chemother 19:858–866CrossRef
Metadaten
Titel
Comparative activities of sitafloxacin against recent clinical isolates in hospitals across China
verfasst von
Shi Wu
Yang Yang
Yan Guo
Dandan Yin
Yonggui Zheng
Renru Han
Li Ding
Demei Zhu
Fupin Hu
Publikationsdatum
19.05.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 11/2021
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-021-04278-3

Weitere Artikel der Ausgabe 11/2021

European Journal of Clinical Microbiology & Infectious Diseases 11/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.